Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...